Elsevier

Journal of Controlled Release

Volume 331, 10 March 2021, Pages 390-403
Journal of Controlled Release

Engineered liposomes targeting the gut–CNS Axis for comprehensive therapy of spinal cord injury

https://doi.org/10.1016/j.jconrel.2021.01.032Get rights and content

Highlights

  • The engineered liposome achieved comprehensive therapeutic effect against SCI and related enteric complications.

  • The engineered liposome permeated through oral absorption barriers, targeted local EGCs and astrocytes.

  • Design of the engineered liposome based on the gut–organ axis makes the gut serve as a “shortcut”.

  • The chitosan-like layer consisted of water-soluble chitosan derivative which overcame the limitations of chitosan.

  • The neuropeptide apamin, stabilized by sulfur replacement with selenium, was adopted as a targeting moiety.

Abstract

Effective curative therapies for spinal cord injury (SCI), which is often accompanied by intestinal complications, are lacking. Potential therapeutic targets include astrocytes and their enteric nervous system counterpart, enteric glial cells (EGCs). Based on shared biomarkers and similar functions of both cell types, we designed an orally administered targeted delivery system in which the neuropeptide apamin, stabilized by sulfur replacement with selenium, was adopted as a targeting moiety, and the liposome surface was protected with a non-covalent cross-linked chitosan oligosaccharide lactate layer. The system effectively permeated through oral absorption barriers, targeted local EGCs and astrocytes after systemic circulation, allowing for comprehensive SCI therapy. Given the involvement of the gut-organ axis in a growing number of diseases, our research may shed light on new aspects of the oral administration route as a bypass for multiple interventions and targeted therapy.

Introduction

The oral route is the primary and most convenient drug administration route that allows for self-administration and is associated with good patient compliance as compared with various other administration routes [1,2]. Therefore, oral dosage forms of drug candidates are a major focus in research, clinics and marketing [3]. However, despite the advancements in targeted delivery systems and smart nanomedicines, progress in the state-of-the-art design and construction of oral delivery systems, especially targeted oral delivery systems, is far from satisfactory [4,5]. On the one hand, the harsh environment in the gastrointestinal (GI) tract has severe impacts on the functionalities of nanomedicines. On the other hand, compared with other administration routes, e.g., the intravenous route, via which delivery systems can rapidly distribute to the target sites, the GI tract acts as an extra barrier, hampering timely accumulation of delivery systems in target sites [6,7]. With the improved knowledge of gut pathology and physiology, it has become clear that gut function is not limited to digestion. In fact, direct connections exist between the gut and various important organs [[8], [9], [10], [11]], such as the gut–liver axis, gut–lung axis, and gut–brain axis. Accumulating evidence suggests that many diseases and their complications are directly or indirectly related to the gut, and the existence of relevant targets in the GI tract provides a substantial basis for the development of relevant treatments [12,13]. With the support of rapid-developing biochemistry and material sciences for targeted drug delivery system design, it is anticipated that, besides being an administration route, the gut will also serve as a “shortcut” for therapeutic agents in the treatment and intervention of various diseases.

Spinal cord injury (SCI) is a pathological damage to the spinal cord induced by trauma, inflammation, and various other causes, with severe symptoms, difficult recovery, and often a life-long course. SCI occurs mostly in young men, resulting in heavy financial and psychological burdens for patients, families, and society. It is estimated that approximately 1,000,000 people suffer from SCI each year [14], however, safe and effective therapeutic agents with simple administration are lacking. Methylprednisolone is the major clinical drug used to treat SCI, but its therapeutic effect is limited, and it causes significant side effects [15].

Recently, astrocytes have emerged as an important treatment target for SCI [16,17]. In normal conditions, astrocytes support the maintenance of the physiological functions of the central nervous system (CNS) [18]. In the pathological process of SCI, however, astrogliosis occurs, in which reactive astrocytes form dense glial scar tissue at the lesions as physical barriers for nerve regeneration, and secrete a series of inhibitors for nerve regeneration [19]. The regulation of astrogliosis and astrocyte characteristics has been suggested as an important strategy for the treatment of SCI [20]. Agents such as curcumin and triptolide reportedly inhibit the activation of astrocytes, thus reducing the formation of glial scar tissues and promoting the regeneration and functional recovery of spinal nerves [[21], [22], [23]]. Efficient delivery of potential therapeutic agents towards the lesion sites, concerning functional moieties and relevant targeted delivery systems with specific recognition of astrocytes and effective penetration through the blood-spinal cord barrier, are areas of focus for such an approach to become effective.

Complications, especially, intestinal complications and relevant dysfunctions, add to the burden of SCI sufferers, severely affecting their quality of life [24,25]. There clearly is an urgent need for relevant and effective therapeutic agents. Enteric glial cells (EGCs), an important component of the gut–CNS axis which resembles astrocytes in morphology, function, and biomarker expression, are a promising target [13]. EGCs are distributed throughout the intestinal system, including the mucous, muscle layers, and the enteric nervous system [26]. Similar to the function of astrocytes in the CNS, EGCs regulate intestinal homeostasis [27], and especially, motor functions [28]. EGCs play an important role in various intestinal dysfunctions, and the toll-like receptor (TLR) expressed on EGCs can be activated by pathological stimuli, leading to activation of the TLR-NFκB pathway and NO production, finally resulting in motor dysfunction [12,29,30]. EGCs may be even directly involved in pathological changes in the CNS [31]. Therefore, we assumed that EGCs may be a potential target for the treatment of SCI and related enteric complications. As EGCs and astrocytes express similar biomarkers, relevant ligands of such specific receptors could be adopted in the construction of dual-targeted delivery systems. It can be expected that, after oral administration, such systems could deliver therapeutic agents to both EGCs after crossing the epithelial layer and astrocytes in the spinal cord after entering the systemic circulation, thus achieving a comprehensive therapeutic effect against SCI and related enteric complications.

Based on the above reasonings, the neuropeptide apamin [32], a ligand of the small conductance calcium-activated potassium (SK) channel that can effectively penetrate the blood-spinal cord barrier and specifically recognize astrocytes and EGCs, was adopted as a targeting moiety, and the disulfide bond in the apamin molecule was replaced with a diselenide bond for enhanced stability in vivo [33]. The conventional liposome was selected as a carrier, and the natural compound curcumin (CUR) was encapsulated to regulate glial cell function [34]. To improve liposome functionality further, the liposome surface was covered with a temporary protective layer of non-covalent cross-linked chitosan oligosaccharide lactate (COL) that facilitates penetration of the intestinal mucosa and dissociates in situ [35]. The delivery system (Fig. 1) was systematically evaluated in molecular and animal studies.

Section snippets

Materials

Curcumin (CUR) was purchased from Rongsheng Biotechnology (Xi'an, China). HSPC and NHS-PEG2000-DSPE were purchased from A.V.T. Pharmaceutical (Shanghai, China). DiIC18(3) (DiI) and DiOC18(3) (DiO) were purchased from US Everbright (Suzhou, China). Chitosan oligosaccharide lactate (COL) and IR-780 were purchased from Sigma-Aldrich (USA). Rabbit anti-S100β antibody was obtained from Abcam (Cambridge, UK). Rabbit anti-claudin 4, anti-MUC5B, anti-Sox10, anti-glial fibrillary acidic protein (GFAP),

Targeting compound synthesis and characterization

We first replaced the disulfide bonds in apamin with diselenide bonds to obtain diseleno bond-stabilized apamin (Se-apamin), which maintained the helical structure of apamin (Fig. 2a). This result was consistent with a three-dimensional (3D) structural model of Se-apamin constructed based on energy minimization in the solvent model, which confirmed that the two molecules have largely coincident structures (Fig. 2a). Analysis of the stability of Se-apamin under simulated physiological conditions

Conclusions

We achieved effective intervention in SCI and related enteric complications through oral drug delivery based on the following two principles: 1) simultaneous recognition of a specific receptor shared by astrocytes and EGCs by a relevant peptide ligand with improved stability, and 2) significant improvement in penetration through oral absorption barriers by coating the liposome with a water-soluble chitosan derivative, which also had an obvious advantage in the preparation process as compared

Author contributions

X.W. and J.W. contributed to this work equally. All authors have prepared and approved the final version of the manuscript.

Declaration of Competing Interest

The authors declare no competing financial interest.

Acknowledgement

The research was financially supported by Natural Science Foundation of Chongqing (cstc2015jcyjBX0100), the National Natural Science Foundation of China (NSFC No. 81673376, 81803472), and Fundamental Research Funds for the Central Universities (XDJK2017D150).

References (93)

  • G.M. Holmes et al.

    Gastrointestinal dysfunction after spinal cord injury

    Exp. Neurol.

    (2019)
  • S. Glickman et al.

    Bowel dysfunction in spinal-cord-injury patients

    Lancet

    (1996)
  • C. Pochard et al.

    Defects in 15-HETE production and control of epithelial permeability by human enteric glial cells from patients with crohn’s disease

    Gastroenterology

    (2016)
  • Z. Wang et al.

    The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer

    Biomaterials

    (2012)
  • Q. Gao et al.

    Synthesis of hierarchical sieve-like mesoporous silica nanoparticle aggregates via centrifugal method for drug delivery system

    Chin. Chem. Lett.

    (2018)
  • Y.Y. Yeap et al.

    Intestinal mucus is capable of stabilizing supersaturation of poorly water-soluble drugs

    J. Control.Release

    (2019)
  • M. Li et al.

    Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: assessed in vitro by everted gut sac and in situ by improved intestinal perfusion

    Int. J. Pharm.

    (2011)
  • J. Zhang et al.

    Biopharmaceutics classification and intestinal absorption study of apigenin

    Int. J. Pharm.

    (2012)
  • P. Zhang et al.

    Toll like receptor 4 (TLR4) mediates the stimulating activities of Chitosan Oligosaccharide on macrophages

    Int. Immunopharmacol.

    (2014)
  • J. Zhuang et al.

    The influence of nanoparticle shape on bilateral exocytosis from Caco-2 Cells

    Chin. Chem. Lett.

    (2018)
  • J.J. McCann et al.

    Optimizing methods to recover absolute FRET efficiency from immobilized single molecules

    Biophys. J.

    (2010)
  • T. Tagami et al.

    MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome

    Biomaterials

    (2011)
  • S. Ge et al.

    Isolation and culture of microvascular endothelial cells from murine spinal cord

    J. Neuroimmunol.

    (2006)
  • H. He et al.

    Adapting liposomes for oral drug delivery

    Acta Pharm. Sin. B

    (2019)
  • Q. Luo et al.

    Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system

    Int. J. Pharm.

    (2011)
  • M. Murata et al.

    Pulmonary delivery of elcatonin using surface-modified liposomes to improve systemic absorption: polyvinyl alcohol with a hydrophobic anchor and Chitosan Oligosaccharide as effective surface modifiers

    Eur. J. Pharm. Biopharm.

    (2012)
  • H. Lee et al.

    Adsorption of plasma proteins onto PEGylated Lipid Bilayers: the effect of PEG size and grafting density

    Biomacromolecules

    (2016)
  • C. Hilgendorf et al.

    Caco-2 versus Caco-2/HT29-MTX Co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport

    J. Pharm. Sci.

    (2000)
  • X. Li et al.

    Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles

    Biomaterials

    (2013)
  • A.L. Davies et al.

    Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury

    Arch. Phys. Med. Rehabil.

    (2007)
  • M.V. Sofroniew

    Molecular dissection of reactive astrogliosis and glial scar formation

    Trends Neurosci.

    (2009)
  • G. Bassotti et al.

    Enteric Glial cells: new players in gastrointestinal motility?

    Lab. Investig.

    (2007)
  • R. Hokari et al.

    Reduced sensitivity of inducible nitric oxide synthase-deficient mice to chronic colitis

    Free Radic. Biol. Med.

    (2001)
  • Y. Gao et al.

    Evaluating accessibility of intravenously administered nanoparticles at the lesion site in rat and pig contusion models of spinal cord injury

    J. Control. Release

    (2019)
  • des Rieux et al.

    Targeted nanoparticles with novel non-peptidic ligands for oral delivery

    Adv. Drug Deliv. Rev.

    (2013)
  • D. Vllasaliu et al.

    Recent advances in oral delivery of biologics: nanomedicine and physical modes of delivery

    Expert Opin. Drug Deliv.

    (2018)
  • W. Shan et al.

    Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin

    ACS Nano

    (2015)
  • S. Zeuzem

    Gut-liver axis

    Int. J. Color. Dis.

    (2000)
  • A. Tripathi et al.

    The gut–liver axis and the intersection with the microbiome

    Nat. Rev. Gastroenterol. Hepatol.

    (2018)
  • K.F. Budden et al.

    Emerging pathogenic links between microbiota and the gut-lung axis

    Nat. Rev. Microbiol.

    (2017)
  • F. Ochoa-Cortes et al.

    Enteric glial cells: a new frontier in neurogastroenterology and clinical target for inflammatory bowel diseases

    Inflamm. Bowel Dis.

    (2016)
  • Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: an systematic analysis for the global burden of disease study 2016

    Lancet Neurol.

    (2019)
  • M.A. Anderson et al.

    Astrocyte scar formation aids central nervous system axon regeneration

    Nature

    (2016)
  • S. Okada et al.

    Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after apinal cord injury

    Nat. Med.

    (2006)
  • V. Rothhammer et al.

    Microglial control of astrocytes in response to microbial metabolites

    Nature

    (2018)
  • K.L. Adams et al.

    The diversity and disparity of the glial scar

    Nat. Neurosci.

    (2018)
  • Cited by (10)

    • Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment

      2023, Chinese Chemical Letters
      Citation Excerpt :

      Various nanocarriers including liposomes, polymer nanocapsules, microemulsions, polymer micelles, dendrimers, and nanomedical crystals have been emerged for the delivery of oral therapeutic drugs. Wang et al. designed engineered liposomes targeting the gut-CNS Axis for comprehensive therapy and realized comprehensive treatment of spinal cord injury [211]. Omar et al. found that oral delivery of controlled release polymer nanocapsules containing trypsin could target the small intestine and protect trypsin from the harsh condition during the process of preparation or the period of storage [212].

    • Ligand-modified nanocarriers for oral drug delivery: Challenges, rational design, and applications

      2022, Journal of Controlled Release
      Citation Excerpt :

      The surface properties, especially the possibility of further modification, are also vital. Given the numerous requirements for the fabrication of oral LMNCs, liposomes, PLGA, CS, PEG, and solid lipid NCs are widely acknowledged in the design of oral LMNCs [85,132–134]. Organic material-based NCs, such as PLGA- and lipid-based NCs, are more biocompatible and easier to take up, whereas inorganic and metal material-based NCs, such as carbon nanotubes and gold-based NCs, are more stable in the gastrointestinal tract and have diverse properties that may be altered for functional delivery [135].

    • Codelivery of minocycline hydrochloride and dextran sulfate via bionic liposomes for the treatment of spinal cord injury

      2022, International Journal of Pharmaceutics
      Citation Excerpt :

      In recent years, nanodelivery systems such as liposomes (Gao et al., 2017), PLGA nanoparticles (Ren et al., 2014), silica nanoparticles (Zhang et al., 2021), metal nanoparticles (Kim et al., 2017), exosomes (Guo et al., 2019) and cell membrane vesicles (Liu et al., 2022) have been reported. Among these, nanoliposomes as a drug delivery system are less toxic, simple to prepare and have a proven process for mass production (Li et al., 2018; Wang et al., 2021). Our previous studies have shown that macrophage-derived membrane nanovesicles have a good effect to target the site of SCI (Liu et al., 2022).

    View all citing articles on Scopus
    1

    These authors contributed equally to this work.

    View full text